Two pandemics are currently afflicting the planet. While our governments focus on the smaller one (COVID-19), the larger one (the Mental Health Crisis) is rapidly spiralling out of control.
MINDCURE increases its strategic investment in ATMA Journey Centers and deploys its iSTRYM digital therapeutics platform.
Drug development is expensive. It is also EXTREMELY lucrative. We take a close look at this revenue potential.
Microdosing has become something of a wellness trend in recent years, gathering traction in Australia and overseas.
Psychedelic stocks have been hammered in recent weeks by general selling pressures on tech stocks. But with corporate coffers full, these companies can weather the storm.
Institutional interest in psychedelics-based TBI research increases, as Wesana closes an oversubcribed CAD$16.1 million financing.
Company Now Is In Two High Growth Rate Global Markets With iSTRYM In The DTx Market, Projected To Reach $56 Billion By 2025 And The Global Psychedelic Market Projected To Reach Over $7.5 Billion By 20281